Suri Anish 4
4 · Cue Biopharma, Inc. · Filed Oct 8, 2021
Insider Transaction Report
Form 4
Suri Anish
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-10-03+33,334→ 108,172 total - Exercise/Conversion
Restricted Stock Units
2021-10-03−33,334→ 0 total→ Common Stock (33,334 underlying) - Tax Payment
Common Stock
2021-10-06$12.97/sh−14,134$183,318→ 94,038 total
Footnotes (3)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Each restricted stock unit award represents a contingent right to receive one share of common stock.
- [F3]On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019.